2. Academic Validation
  3. Novel L-xylose derivatives as selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes

Novel L-xylose derivatives as selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes

  • J Med Chem. 2009 Oct 22;52(20):6201-4. doi: 10.1021/jm900951n.
Nicole C Goodwin 1,  Ross Mabon,  Bryce A Harrison,  Melanie K Shadoan,  Zheng Y Almstead,  Yiling Xie,  Jason Healy,  Lindsey M Buhring,  Christopher M DaCosta,  Jennifer Bardenhagen,  Faika Mseeh,  Qingyun Liu,  Amr Nouraldeen,  Alan G E Wilson,  S David Kimball,  David R Powell,  David B Rawlins
Affiliations

Affiliation

  • 1 Department of Medicinal Chemistry, Lexicon Pharmaceuticals, 350 Carter Road, Princeton, New Jersey 08540, USA. [email protected]
PMID: 19785435 DOI: 10.1021/jm900951n
Abstract

The prevalence of diabetes throughout the world continues to increase and has become a major health issue. Recently there have been several reports of inhibitors directed toward the sodium-dependent glucose cotransporter 2 (SGLT2) as a method of maintaining glucose homeostasis in diabetic patients. Herein we report the discovery of the novel O-xyloside 7c that inhibits SGLT2 in vitro and urinary glucose reabsorption in vivo.

Figures